Log in with your email address username.


[Correspondence] New guideline for idiopathic pulmonary fibrosis

The Lancet Editors (July 25, p 312)1 highlight the publication of a new international clinical guideline for the treatment of idiopathic pulmonary fibrosis.2 This updated guideline provides conditional recommendations for use of nintedanib and pirfenidone to treat patients with idiopathic pulmonary fibrosis and emphasises the role of individual patients’ preferences and values in treatment decisions.2 According to the Editors, this guideline suggests that nintedanib and pirfenidone might be suitable for some patients, whereas the conditional recommendation, according to the guideline, is when “the majority of individuals in this situation would want the suggested course of action, but many would not”.